Some hoped legalization of recreational cannabis in 2018 would also ease hurdles on the medical side, which include Mastering how successful or ineffective it is for particular conditions, lowering stigma and purple tape, as well as costs.The uncertainty has knocked down Tilray's share price by much more than 90%. This has compelled CEO Irwin Simon